The melanin-concentrating hormone receptor 1, a novel target of autoantibody responses in vitiligo.
about
Vitiligo: interplay between oxidative stress and immune systemHighlights in pathogenesis of vitiligoVitiligo--part 1Mechanisms of spatial and temporal development of autoimmune vitiligo in tyrosinase-specific TCR transgenic mice.Mapping of melanin-concentrating hormone receptor 1 B cell epitopes predicts two major binding sites for vitiligo patient autoantibodies.Mapping of human autoantibody binding sites on the calcium-sensing receptor.Evolution, immunity and the emergence of brain superautoantigensIncreased Risk of Metabolic Syndrome in Patients with Vitiligo.Association of CYP2C9 Genetic Variants with Vitiligo.Association of neuropeptide Y (NPY), interleukin-1B (IL1B) genetic variants and correlation of IL1B transcript levels with vitiligo susceptibilityAutoantibodies as diagnostic and predictive markers of vitiligo.Therapeutic implications of autoimmune vitiligo T cells.CD8+ T cells from vitiligo perilesional margins induce autologous melanocyte apoptosis.Melanin-concentrating hormone as a mediator of intestinal inflammation.Autoimmunity as an aetiological factor in vitiligo.Activating autoantibodies against the calcium-sensing receptor detected in two patients with autoimmune polyendocrine syndrome type 1.Cyclic peptides as potential therapeutic agents for skin disorders.Cellular models for the study of the pharmacology and signaling of melanin-concentrating hormone receptors.Vitiligo and associated autoimmune disease: retrospective review of 300 patients.The pathogenesis of vitiligo.The delicate balance of melanoma immunotherapy.Oxidative stress and immune system in vitiligo and thyroid diseases.Patients affected by vitiligo and autoimmune diseases do not show antibodies interfering with the activity of the melanocortin 1 receptor.Function-blocking autoantibodies to the melanin-concentrating hormone receptor in vitiligo patients.Detection of auto antibodies and transplantation of cultured autologous melanocytes for the treatment of vitiligo.Autoantibodies in vitiligo patients are not directed to the melanocyte differentiation antigen MelanA/MART1.Absence of tyrosinase-related protein-2/dopachrome tautomerase transcripts in PBMCs from vitiligo patients.Vitiligo and Autoimmune Thyroid Disorders.Vitiligo patients from India (Mumbai) show differences in clinical, demographic and autoantibody profiles compared to patients in western countries.T cell subpopulations and IL-2R in vitiligo.Vitiligo immune reconstitution inflammatory syndrome (IRIS)-An incidental finding in a tertiary teaching hospital in southeast Nigeria.Anti-Melanoma immunity and local regression of cutaneous metastases in melanoma patients treated with monobenzone and imiquimod; a phase 2 a trial.The antibody response against MART-1 differs in patients with melanoma-associated leucoderma and vitiligo.Autoantibodies against tyrosine hydroxylase in patients with non-segmental (generalised) vitiligo
P2860
Q26824504-075206A2-5EF5-46D2-A81F-816A8BB6597CQ26851509-6CA955F6-D383-4763-8063-64D786EDC8EBQ27028001-B84480A7-C71E-4A94-B3D3-32F095B8944CQ30433217-D719FBB8-4911-4909-8294-439FAE4BD762Q33422038-A1AB4F19-6EE9-432C-A662-296E12578538Q33478693-83FD8F24-9C12-436A-8100-F9C670CFEE9CQ33642424-6351210F-3193-4778-AA85-AC93E42C71EFQ33745258-0D68A85E-2FB5-4E34-A203-C241B121EDB2Q33801991-D5E6405F-7510-4593-A6E6-21A25BF55A2BQ34183603-D638FC1C-BB2A-40BD-9350-D61DC7BFA3FAQ35934690-5750CD5E-13FE-4462-819A-A2790B54A6E0Q36292745-36137762-20B8-422F-ACC6-61A64C78FAC9Q36610648-63C30D70-E761-4731-8BE9-33FA91A978BFQ36802510-16D43F94-A392-4E59-A1AD-56F87D2531AAQ36894318-A4A1FA83-BF1B-402C-8129-810BF6D73379Q37482693-20A25FF4-FCC3-4DCD-A9D7-28CD97AA468CQ37766522-7F1A0D1C-6ABF-4DC0-BE07-E9AD0E0C5C3EQ37810288-C02AFD3B-6D15-496C-A7FB-ED8D4E8AE49CQ38025488-8DE79664-30AF-4412-96C0-4F873D17E098Q38106804-0C7FE922-460E-482D-BD2D-24115FBB34B0Q38288116-69714AFC-EC8F-4082-98BB-8E72029D2878Q38403600-571DA738-A9E5-450D-9033-83ACE06678A4Q39723783-1244F08C-AB58-47E9-93C4-69C1B4EF2632Q40282263-291D655A-FDFD-433F-9742-1C6C33DFD56BQ42329773-D8FE8366-7729-40B2-A641-384E1ABAD5A4Q44116002-DCA3D58B-2D28-4F2C-AEE7-C7C5A6084982Q46089485-903B6289-83B3-466E-8641-5A503094264BQ46256690-61124E8F-BE86-45C7-BD45-CD5B42DDC232Q46953146-359EDFC1-C0FF-453C-A431-9E47CA148F13Q47435954-D073A298-D299-413B-9792-D6512C96C524Q47547329-F5FACE5E-0B50-4CE7-AD33-8FD85BBC9D4AQ52597538-91547A98-A215-4CC9-AA65-DB7942A8A9A3Q55058396-35474729-934D-4756-A448-EEEED1CE786AQ56892977-7E8EA5C5-DE66-45D5-A529-B45C1C0D1F1A
P2860
The melanin-concentrating hormone receptor 1, a novel target of autoantibody responses in vitiligo.
description
2002 nî lūn-bûn
@nan
2002 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
The melanin-concentrating horm ...... ntibody responses in vitiligo.
@ast
The melanin-concentrating horm ...... ntibody responses in vitiligo.
@en
type
label
The melanin-concentrating horm ...... ntibody responses in vitiligo.
@ast
The melanin-concentrating horm ...... ntibody responses in vitiligo.
@en
prefLabel
The melanin-concentrating horm ...... ntibody responses in vitiligo.
@ast
The melanin-concentrating horm ...... ntibody responses in vitiligo.
@en
P2093
P2860
P356
P1476
The melanin-concentrating horm ...... ntibody responses in vitiligo.
@en
P2093
Anthony P Weetman
Brian E Hawes
David J Gawkrodger
E Helen Kemp
Elizabeth A Waterman
Kim O'Neill
Philip F Watson
Raju V S R K Gottumukkala
P2860
P304
P356
10.1172/JCI0214643
P407
P577
2002-04-01T00:00:00Z